IVF Services
Sperm Lab
Appointment Info
Contact Us
Donate Your Eggs
Educational Info
Info in Spanish
Terms of Use
Legal Notices

Back to Top
University of Colorado Denver

Buy Clomid (Clomiphene Citrate) tablets online

How and where to order Clomid (Clomifene) 25, 50, 100 mg tablets or capsules online:

Shop:DFH PHARMACY - 10% discount coupon DFH10
Prices:from $0.42 per pill
Forms:25 mg, 50 mg, 100 mg tablets
Quantity:30-360 pills
Type:Clomiphene (Clomifene) Citrate brand, Clomid generic
Payment:Visa, Mastercard, AmEx, Bitcoin
Delivery:Regular and express mail service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Clomid (Clomiphene Citrate) tablets are indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning Clomid therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.

Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of Clomiphene (Clomid) should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles).

Clomid tablets are indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below:

  • Patients who are not pregnant.
  • Patients without ovarian cysts. Clomiphene Citrate (Clomid) should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of Clomid treatment.
  • Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present.
  • Patients with normal liver function.

    In addition, patients selected for Clomid therapy should be evaluated in regard to the following:

  • Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy.
  • Primary Pituitary or Ovarian Failure. Clomiphene therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure.
  • Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to Clomid therapy in this population.
  • Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility.
  • Uterine Fibroids. Caution should be exercised when using Clomiphene in patients with uterine fibroids due to the potential for further enlargement of the fibroids.

    There are no adequate or well-controlled studies that demonstrate the effectiveness of Clomid pills in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of Clomid is not known.

    Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (ie, Clomid in conjunction with other ovulation-inducing drugs). Similarly, there is no standard Clomiphene tablets regimen for ovulation induction in in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, Clomid tablets are not recommended for these uses.

    Dosage and administration:

    General considerations

    The workup and treatment of candidates for Clomid (Clomiphene Citrate) tablets therapy should be supervised by physicians experienced in management of gynecologic or endocrine disorders. Patients should be chosen for therapy with Clomid only after careful diagnostic evaluation. The plan of therapy should be outlined in advance. Impediments to achieving the goal of therapy must be excluded or adequately treated before beginning Clomid. The therapeutic objective should be balanced with potential risks and discussed with the patient and others involved in the achievement of a pregnancy.

    Ovulation most often occurs from 5 to 10 days after a course of Clomid. Coitus should be timed to coincide with the expected time of ovulation. Appropriate tests to determine ovulation may be useful during this time.

    Recommended dosage

    Treatment of the selected patient should begin with a low dose, 50 mg daily (1 tablet) for 5 days. The dose should be increased only in those patients who do not ovulate in response to cyclic 50 mg Clomid. A low dosage or duration of treatment course is particularly recommended if unusual sensitivity to pituitary gonadotropin is suspected, such as in patients with polycystic ovary syndrome.

    The patient should be evaluated carefully to exclude pregnancy, ovarian enlargement, or ovarian cyst formation between each treatment cycle.

    If progestin-induced bleeding is planned, or if spontaneous uterine bleeding occurs prior to therapy, the regimen of 50 mg daily for 5 days should be started on or about the 5th day of the cycle. Therapy may be started at any time in the patient who has had no recent uterine bleeding. When ovulation occurs at this dosage, there is no advantage to increasing the dose in subsequent cycles of treatment.

    If ovulation does not appear to occur after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single daily dose) for 5 days should be given. This course may be started as early as 30 days after the previous one after precautions are taken to exclude the presence of pregnancy. Increasing the dosage or duration of therapy beyond 100 mg/day for 5 days is not recommended.

    The majority of patients who are going to ovulate will do so after the first course of therapy. If ovulation does not occur after three courses of therapy, further treatment with Clomid is not recommended and the patient should be reevaluated. If three ovulatory responses occur, but pregnancy has not been achieved, further treatment is not recommended. If menses does not occur after an ovulatory response, the patient should be reevaluated. Long-term cyclic therapy is not recommended beyond a total of about six cycles.

    Dosage forms and strengths:

    Clomid (Clomiphene Citrate) tablets 25 mg, 50 mg, 100 mg.


  • Hypersensitivity. Clomid is contraindicated in patients with a known hypersensitivity or allergy to clomiphene citrate or to any of its ingredients.
  • Pregnancy. Pregnancy Category X. Clomid pills use in pregnant women is contraindicated, as Clomiphene does not offer benefit in this population.
    Available human data do not suggest an increased risk for congenital anomalies above the background population risk when used as indicated. However, animal reproductive toxicology studies showed increased embryo-fetal loss and structural malformations in offspring. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risks to the fetus.
  • Liver Disease. Clomid therapy is contraindicated in patients with liver disease or a history of liver dysfunction.
  • Abnormal Uterine Bleeding. Clomiphene is contraindicated in patients with abnormal uterine bleeding of undetermined origin.
  • Ovarian Cysts. Clomid is contraindicated in patients with ovarian cysts or enlargement not due to polycystic ovarian syndrome
  • Clomid is contraindicated in patients with uncontrolled thyroid or adrenal dysfunction or in the presence of an organic intracranial lesion such as pituitary tumor.

    Drug interactions:

    Drug interactions with clomiphene have not been documented.


    Signs and symptoms

    Toxic effects accompanying acute overdosage of clomiphene have not been reported. Signs and symptoms of overdosage as a result of the use of more than the recommended dose during CLOMID therapy include nausea, vomiting, vasomotor flushes, visual blurring, spots or flashes, scotomata, ovarian enlargement with pelvic or abdominal pain.

    Oral LD50: The acute oral LD50 of clomiphene is 1700 mg/kg in mice and 5750 mg/kg in rats. The toxic dose in humans is not known.

    Dialysis: It is not known if clomiphene is dialyzable.


    In the event of overdose, appropriate supportive measures should be employed in addition to gastrointestinal decontamination.

    Adverse reactions, side effects:

    Clomid tablets, at recommended dosages, is generally well tolerated. Side effects usually have been mild and transient and most have disappeared promptly after treatment has been discontinued. Adverse experiences reported in patients treated with clomiphene citrate are following:

  • Abdominal-pelvic discomfort/distention/bloating
  • Abnormal uterine bleeding
  • Breast discomfort
  • Headache
  • Nausea and vomiting
  • Ovarian enlargement
  • Vasomotor flushes
  • Visual symptoms

    Where to buy clomiphene online:

    To purchase Clomiphene Citrate 50 mg, 100 mg, 25 mg tablets from reliable online pharmacies and drugstores please use resources described above on this webpage.

    Here is a list of popular medications containing clomiphene as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
  • Tablets; Oral; Clomiphene Citrate 25 mg, 50 mg, 100 mg
  • Sanofi
  • Clostilbegyt
  • Tablets; Oral; Clomiphene Citrate 50 mg
  • Egis
  • Delfi Singapore
  • Medphano Arzneimittel
  • Mekim
  • Pahang Pharmacy
  • Sime Darby Marketing
  • Fertomid
  • Tablets; Oral; Clomiphene Citrate 25 mg, 50 mg, 100 mg
  • Cipla
  • Ova-Mit
  • Tablets; Oral; Clomiphene Citrate 50 mg
  • Ebewe Pharma
  • Corbridge Group
  • Goldplus Universal
  • IDS Group
  • JDH Pharmaceutical
  • Pharmadica
  • Primal Chemical
  • Remedica
  • Ovofar
  • Tablets; Oral; Clomiphene Citrate 50 mg
  • Organon
  • Infar India
  • Serophene
  • Tablets; Oral; Clomiphene Citrate 50 mg
  • Serono
  • Allphar Services
  • Antah Pharma
  • Apex Pharma Marketing
  • DKSH
  • Douglas Pharmaceuticals
  • Four Star
  • Merck
  • Pharmascience

  • University of Colorado Denver
    Advanced Reproductive Medicine

    Anschutz Medical Campus Office
    Location: 1635 Aurora Court, Aurora, CO 80045
    Mailing: PO Box 6510, Mail Stop F701, Aurora, CO 80045
    Tel: 720.848.1690
    Toll-free: 1.888.899.7441
    Fax: 720.848.1678
    Colorado Springs Office
    4125 Briargate Parkway, Suite 350
    Colorado Springs, CO 80920
    Tel: 719.314.3333
    Fax: 719.314.3344

    Detailed Directions to Our Offices